ORPHA:544493
Streptococcus pneumoniae-associated hemolytic uremic syndrome
Also known as: S. pneumoniae-associated HUS · SP-HUS
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
87
53th percentile
Trials
0
Interventional, condition-specific
Researchers
420
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0035293
- UMLS:C5680164
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
87 matched papers (49 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 41 for broader category hemolytic-uremic syndrome
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
87
87 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
87 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
49 in the last 10 years · high confidence · 53th percentile (publications denominator)
Phrase hits: 87 · MeSH hits: 0
Who's working on it?
420
Distinct author names in 87 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Kaplan BS6 papers · 2020
Division of Nephrology, Children's Hospital, University of Philadelphia 19104.
Papers in Europe PMC - 02Copelovitch L5 papers · 2020
Department of Pediatrics, Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Papers in Europe PMC - 03Prohászka Z5 papers · 2025
Research Laboratory, Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
Papers in Europe PMC - 04Kellner JD3 papers · 2025
Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Papers in Europe PMC - 05van den Heuvel LP3 papers · 2025
Department of Pediatric Nephrology (804), Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Papers in Europe PMC - 06Agarwal HS2 papers · 2021
Department of Pediatric Critical Care, Cleveland Clinic Children's, Cleveland, Ohio.
Papers in Europe PMC - 07Arjona E2 papers · 2021
Department of Molecular Biomedicine, Centre for Biological Research, Madrid, Spain.
Papers in Europe PMC - 08Baas LM2 papers · 2025
Department of Pediatric Nephrology, Radboud University Medical Centre, Amalia Children's Hospital, Nijmegen, Netherlands.
Papers in Europe PMC - 09Bachelot Y2 papers · 2023
Applied Systems Biology, HKI-Center for Systems Biology of Infection, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI) , Jena, Germany.
Papers in Europe PMC - 10Bangstad HJ2 papers · 2016
Department of Pediatrics, Oslo University Hospital, Oslo, Norway.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 41 trials are registered for hemolytic-uremic syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
41 interventional trials matched hemolytic-uremic syndrome, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hemolytic-uremic syndrome
41
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07308574·RECRUITING·Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Conditions: aHUS · Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05805202·RECRUITING·Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05726916·RECRUITING·Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Conditions: Hypertensive Emergency-associated Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05935215·RECRUITING·Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05996731·RECRUITING·Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
Conditions: Atypical Hemolytic Uremic Syndrome · Membranoproliferative Glomerulonephritis · Autosomal Dominant Polycystic Kidney · Healthy·Matched via name phrase
- NCT05684159·NOT YET RECRUITING·Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
Conditions: aHUS - Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT06389474·RECRUITING·Efficacy of INM004 in Children With STEC-HUS
Conditions: Hemolytic-Uremic Syndrome·Matched via name phrase
- NCT05219110·RECRUITING·Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection · Hemolytic-Uremic Syndrome·Matched via name phrase
- NCT05795140·RECRUITING·Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Streptococcus pneumoniae-associated hemolytic uremic syndrome" OR "S. pneumoniae-associated HUS" OR "SP-HUS"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Streptococcus pneumoniae-associated hemolytic uremic syndrome" OR "S. pneumoniae-associated HUS" OR "SP-HUS" OR "infection-related hemolytic uremic syndrome"
Recall-expansion terms: infection-related hemolytic uremic syndrome
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemolytic-uremic syndrome"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T18:17:27.574Z